AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 83 min read$NTLA

NTLA Looks 4.0% Undervalued on GF Value™ as FDA Advances Lonvo-z

Intellia Therapeutics (NTLA) received FDA Priority Review for lonvo-z, a CRISPR-based therapy for hereditary angioedema, with a decision expected by March 2027. The company's P/S ratio is 25.13, below its historical median of 32.3x, and its GF Value™ suggests it is 4.0% undervalued. Insider activity shows net selling, while six top gurus hold the stock, with mixed recent activity.

Original reporting
gurufocus.com
Published Sep 8, 2026, 12:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 2:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$NTLA
Bullish
high confidence
Mentioned
$NTLA
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$NTLABullishHigh
01

Why it matters

Regulatory acceptance reduces timeline uncertainty, likely prompting short‑term buying pressure while long‑term risk remains tied to trial outcomes.

02

Market read

A rare regulatory catalyst for a biotech, offering a clear short‑term trade idea.

03

What to watch

Potential competition from other CRISPR players and the need for commercial partnerships post‑approval.

Relevance 8/10Novelty 9/10Timing: today

Background

Intellia Therapeutics (NTLA) is a clinical‑stage biotech focused on CRISPR‑based in‑vivo treatments, with a market cap of ~$1.8B.

Company-level read

Ticker impact

$NTLABullishHigh confidence
Context

FDA accepted Intellia Therapeutics' BLA for lonvo‑z and granted Priority Review, a fresh regulatory milestone.

Expected impact

Potential upside of 10‑15% over the next 3‑6 months if the review proceeds without issues.

Evidence & confidence

Regulatory clearance is a material catalyst for a clinical‑stage biotech; the market has already priced some upside, but the lack of an advisory committee further reduces uncertainty.

Market effects

Sector

Strengthens the broader CRISPR/gene‑editing sector as a proof point for in‑vivo therapies.

Regional

Positive for US biotech indices and Nasdaq‑listed biotech ETFs.

Global

Highlights US regulatory leadership, may influence global investors' exposure to gene‑editing pipelines.

Counterpoint

What could challenge this read

The therapy remains unproven; execution risk and high cash burn could limit upside despite regulatory progress.

Key entities

  • company
    Intellia Therapeutics Inc

    Developer of the CRISPR therapy lonvo‑z.

  • regulator
    FDA

    U.S. Food and Drug Administration granting Priority Review.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 9
$NTLAMedAI 8/10

FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

Intellia Therapeutics (NTLA) announced the FDA accepted and granted priority review to its BLA for lonvoguran ziclumeran, a CRISPR-based therapy for hereditary angioedema (HAE). A decision is expected by March 2027. The therapy showed an 87% reduction in attacks in a phase III study. NTLA shares have risen 41.7% year-to-date. The company also has another CRISPR therapy, nexiguran ziclumeran, in development with Regeneron (REGN).

tradingview.com3 min
SEP 9
$NTLAMedAI 9/10

Intellia's 'Lonvo-Z' Enters FDA Priority Review — Bids to Become World's First In Vivo CRISPR Therapy — BigGo Finance

Intellia Therapeutics' hereditary angioedema treatment, Lonvo-Z, received FDA Priority Review. If approved, it would be the first in vivo CRISPR therapy. The FDA set a PDUFA target action date of March 10, 2027. Lonvo-Z showed an 87% reduction in attacks in a Phase 3 study. Intellia's stock has risen over 35% year-to-date, with ARK Invest recently increasing its stake.

finance.biggo.com2 min
SEP 8
$NTLAHighAI 8/10

Intellia Announces FDA Acceptance of BLA for Lonvo-z with PDUFA Date March 10, 2027

Intellia Therapeutics announced FDA acceptance of its BLA for lonvo-z, a CRISPR-based therapy, with a Priority Review and PDUFA action date of March 10, 2027. The FDA does not plan to hold an advisory committee. If approved, lonvo-z would be the first in vivo CRISPR therapy, supported by Phase 3 data showing an 87% reduction in mean monthly attacks and a 62% attack-free rate.

tradingview.com1 min
SEP 8
$NTLAHighAI 8/10

NTLA Looks 4.8% Undervalued on GF Value™ Amid FDA Priority Revie

Intellia Therapeutics (NTLA) shares rose after the FDA granted priority review for its CRISPR-based therapy lonvo-z, targeting hereditary angioedema. The company's P/S ratio is 24.91, below its historical median, suggesting market expectations of future growth. GuruFocus' GF Value™ estimates NTLA is 4.8% undervalued at $12.63 per share, with a GF Score™ of 70/100.

gurufocus.com2 min
SEP 8
$NTLAHighAI 8/10

Why is Intellia Therapeutics stock rallying today?

Intellia Therapeutics (NTLA) stock rose 4.1% in pre-market trading after the FDA accepted its Biologics License Application for lonvoguran ziclumeran and granted Priority Review. The FDA set a target action date of March 10, 2027, and indicated no advisory committee meeting is planned. The application is based on Phase 3 trial data showing an 87% reduction in monthly HAE attacks. Citizens analysts reiterated a $30.00 price target, citing significant value in the HAE opportunity.

investing.com2 min